Acute Respiratory Distress Syndrome (ARDS) Market Set to Reach $2.17 Billion by 2029 with 11.1% Yearly Growth

What industry-specific factors are fueling the growth of the acute respiratory distress syndrome (ards) market?
The rise in pneumonia cases is anticipated to fuel the growth of the Acute Respiratory Distress Syndrome (ARDS) market. Pneumonia, an infection impacting one or both lungs and leading to fluid or pus accumulation in the lungs' air sacs or alveoli, prompts an inflammatory reaction in the lungs. This inflammation increases blood vessel permeability and fluid leakage into the alveoli, hindering the exchange of oxygen and carbon dioxide and leading to breathing discomfort. For instance, data from the UK-based Centre for Tropical Medicine and Global Health in 2023 revealed a significant increase in pneumonia cases in Kenya, with 793,864 reported cases in 2022-2023 compared to 477,186 cases in 2020-2021. Hence, the escalating incidence rates of pneumonia are driving the ARDS market's growth. Acute Respiratory Distress Syndrome (ARDS) Market Driver: The Rise in Respiratory Diseases Is Expected to Positively Impact the ARDS market

Get Your Acute Respiratory Distress Syndrome (ARDS) Market Report Here:
https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

What Is the projected market size and growth rate for the acute respiratory distress syndrome (ards) market?
The market for acute respiratory distress syndrome (ARDS) has been expanding quickly in the past few years. Expecting to increase from $1.29 billion in 2024 to $1.42 billion in 2025, the market anticipates a compound annual growth rate (CAGR) of 10.4%. The historical momentum can be credited to progress in critical care medicine, an older populace, advancements in pulmonary rehabilitation, and the integration of multidisciplinary care teams.

A substantial increase in the size of the acute respiratory distress syndrome (ARDS) market is anticipated in the coming years. The market is projected to expand to $2.17 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.1%. This surge during the projection period is ascribed to advances in global healthcare readiness, vaccine creation and disease management, telemedicine and distant monitoring, and patient-focused care models. Key upcoming trends in this period are artificial lungs, bespoke ventilation plans, lung protective ventilation, and special drug treatments for different ARDS subtypes.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

What new trends are reshaping the acute respiratory distress syndrome (ards) market and its opportunities?
Leading firms in the acute respiratory distress syndrome (ARDS) market are concentrating their efforts on the development of novel drugs and supplements, including Aviptadil and HSP90 inhibitors, among others to maintain a leading position in the market. Specifically, Aviptadil is a fabricated vasoactive intestinal peptide (VIP) with a specific binding function to lung alveolar type II cell receptors. As an example, in November 2022, Zuventus Healthcare Ltd., an Indian pharmaceutical manufacturing firm, introduced Aviptadil as a treatment for acute respiratory distress syndrome. Aviptadil, as a vasoactive intestinal peptide supplement, enhances respiration and reduces death risks among ARDS patients. The supplement achieves this by safeguarding and renewing Type-2 Pneumocytes, rejuvenating Type-1 Pneumocytes, augmenting surfactant synthesis, and inhibiting IL-6 (interleukin 6) and tumor necrosis factor (TNF)-alpha.

What major market segments define the scope and growth of the acute respiratory distress syndrome (ards) market?
The acute respiratory distress syndrome (ARDS) market covered in this report is segmented -

1) By Type: Diagnosis, Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

Subsegments:
1) By Diagnosis: Imaging Tests, Blood Tests, Lung Function Tests, Other Diagnostic Methods
2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care, Other Treatment Options

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13005

Which region dominates the acute respiratory distress syndrome (ards) market?
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which key market leaders are driving the acute respiratory distress syndrome (ards) industry growth?
Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

What Is Covered In The Acute Respiratory Distress Syndrome (ARDS) Global Market Report?

• Market Size Forecast: Examine the acute respiratory distress syndrome (ards) market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the acute respiratory distress syndrome (ards) market for a structured understanding.
• Key Players Overview: Analyze major players in the acute respiratory distress syndrome (ards) market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the acute respiratory distress syndrome (ards) market.
• Segment Contributions: Evaluate how different segments drive overall growth in the acute respiratory distress syndrome (ards) market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the acute respiratory distress syndrome (ards) market.
• Industry Challenges: Identify potential risks and obstacles affecting the acute respiratory distress syndrome (ards) market.
• Competitive Landscape: Review strategic developments in the acute respiratory distress syndrome (ards) market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.